{"id":30169,"date":"2026-04-15T04:33:00","date_gmt":"2026-04-14T20:33:00","guid":{"rendered":"https:\/\/csccm.org.cn\/?p=30169"},"modified":"2026-04-15T05:57:25","modified_gmt":"2026-04-14T21:57:25","slug":"jama-netw-open%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e6%8b%a9%e6%9c%9f%e6%89%8b%e6%9c%af%e6%97%b6%e7%9b%b4%e6%8e%a5%e5%8f%a3%e6%9c%8d%e6%8a%97%e5%87%9d%e8%8d%af%e7%9a%84%e6%b0%b4%e5%b9%b3","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=30169","title":{"rendered":"[JAMA Netw Open\u53d1\u8868\u8bba\u6587]\uff1a\u62e9\u671f\u624b\u672f\u65f6\u76f4\u63a5\u53e3\u670d\u6297\u51dd\u836f\u7684\u6c34\u5e73"},"content":{"rendered":"\n<p>Original Investigation&nbsp;<\/p>\n\n\n\n<p>Surgery<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Direct Oral Anticoagulant Levels at Time of Elective Surgery<\/h1>\n\n\n\n<h3 class=\"wp-block-heading\">Eleonora&nbsp;Camilleri,&nbsp;Payam&nbsp;Shahbabai,&nbsp;Mandana&nbsp;Rad,&nbsp;et al<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">JAMA Netw Open 2026;9;(2):e2555875.&nbsp;doi:10.1001\/jamanetworkopen.2025.55875<\/h3>\n\n\n\n<p>Key Points<\/p>\n\n\n\n<p><strong>Question<\/strong>&nbsp;&nbsp;What proportion of patients have elevated residual direct oral anticoagulant (DOAC) levels before an elective procedure when discontinuing treatment according to a standardized protocol (1 day before moderate bleeding-risk procedures and 2 days before high bleeding-risk procedures, with adjustments based on the patient\u2019s kidney function)?<\/p>\n\n\n\n<p><strong>Findings<\/strong>&nbsp;&nbsp;In this cohort study of 257 patients, 7.6% had elevated DOAC levels of 30 ng\/mL or higher before the procedure. Among those receiving apixaban, this proportion was higher (13.6%).<\/p>\n\n\n\n<p><strong>Meaning<\/strong>&nbsp;&nbsp;These results suggest that the standardized interruption protocol is associated with DOAC levels below 30 ng\/mL, although the proportion of patients with levels of 30 ng\/mL or greater was higher among those receiving apixaban.<a><\/a><\/p>\n\n\n\n<p>Abstract<\/p>\n\n\n\n<p><strong>Importance<\/strong>&nbsp;&nbsp;Before elective surgery, direct oral anticoagulants (DOACs) are discontinued following a standardized protocol. However, this could result in insufficient lowering of DOAC levels that could increase bleeding risk.<\/p>\n\n\n\n<p><strong>Objective<\/strong>&nbsp;&nbsp;To estimate the proportion of patients with elevated DOAC levels at the time of elective surgery, evaluate factors associated with DOAC levels, and examine associated blood loss.<\/p>\n\n\n\n<p><strong>Design, Setting, and Participants<\/strong>&nbsp;&nbsp;This cohort study (DOAC Level Prior to Incision [DALI]) assessed adult patients prescribed a DOAC (apixaban, dabigatran, or rivaroxaban) for any indication and at any dose, undergoing an elective procedure requiring DOAC interruption between May 27, 2018, and February 25, 2024, at 2 Dutch hospitals.<\/p>\n\n\n\n<p><strong>Exposure<\/strong>&nbsp;&nbsp;Standardized interruption protocol (1 day before moderate- and 2 days before high bleeding-risk procedures) with interruption adjustments for the patient\u2019s kidney function.<\/p>\n\n\n\n<p><strong>Main Outcomes and Measures<\/strong>&nbsp;&nbsp;Blood was drawn immediately before surgery to determine DOAC levels (by liquid chromatography\u2013mass spectrometry). Proportions of preoperative DOAC levels of 30 ng\/mL or higher and their 95% CIs were estimated, stratified by DOAC type and surgical bleeding risk. Factors associated with DOAC levels were identified through multivariable linear regression. Surgical blood loss and 30-day postoperative complications were described according to DOAC concentrations.<\/p>\n\n\n\n<p><strong>Results<\/strong>\u00a0\u00a0The study was terminated after including 257 patients (100 receiving apixaban, 100 receiving rivaroxaban, and 57 receiving dabigatran due to the slow inclusion rate of those receiving dabigatran; median [IQR] age, 72 [66-78] years; 173 male [67%]); 212 patients (82%) underwent a high bleeding-risk operation. Preprocedural DOAC levels were 30 ng\/mL or higher in 7.6% (95% CI, 4.9%-11.6%) of patients. Dabigatran and rivaroxaban had similar proportions, whereas 13.1% (95% CI, 7.8%-21.2%) of patients treated with apixaban had levels of 30 ng\/mL or higher. Treatment with apixaban, decreased kidney function, and a shorter interruption time were associated with higher levels. Surgical blood loss (median [range], 0 [0-4250] mL) was not associated with DOAC levels. Twelve patients (4.7%; 95% CI, 2.7%-8.0%), who all had DOAC levels less than 30 ng\/mL, experienced major bleeding.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jamanetworkopen\/939778\/zoi251485f1_1769548137.30241.png?Expires=1777582568&amp;Signature=obh7Xe~k3GhP0LaS5U-38VXCmycrn3GQXVBdj9W0iaEYYG9g5Sb7t~7Pn05PKdra~X56~I7vNsjuU3ro2Jc31P9ToFbmJbtVFAYzRKZF7V6TuNSY0dEp5zacpV7aXGOSUIaLIOltfbnTcA-tcuqG6VQbMIjzjYYn5KhdtgHUVdoOkjppqBt1N~NF3JDfhEjVm-wTGFB03Mru1q2P9d8dFc2ZDvBaNJypB0jZgGXLi41JGFILsRIO5RKwp~DvaUJzoEa~BLl2SoYVWedxJcLjfO4del3AI~a-d1YGJD0u969eqqcYVBS3w0TPLcSFY8M1-xQ15Kufk-ga6TWlPnVLpA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jamanetworkopen\/939778\/zoi251485f2_1769548137.40044.png?Expires=1777582568&amp;Signature=08vYfJnwvcISza378aMk18hMoQCwbGcleb71lPRlftNVYDCl9~IKgoPlwktSkdDvq~3diYExr3R5IfI8SBQvMuAdln8xRK8iMQNo9wqFAUX5XKeLVsCuFu278CItx-CEk38VOZoKWW-eyYnlNANo0zy2zJz6OXXinSB0dLzirlAk4wvYt2llkwFJ~i2ugRJUlrwk5yexQaLT0uyqZvyRNworbpvpv0nywdoLUSv7t-3nyj2~Rvooi-izblYXAEmzqcNLDk6MsQ5y4Q8SoosxTRZmC-fZzpihXqIfKVH~H-CsU0UP1DMiRXPOof1yf-HYEVShjmtSGcuJ0kiM8dN2cw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jamanetworkopen\/939778\/zoi251485t1_1769548137.38044.png?Expires=1777582568&amp;Signature=09dzXpUuEKTl9o15ZYCTeFEVoq3fNh0vs9jupXhpYepFck-CBZ87jdeMew~YT0o16MqT00DCStqK5dkzFrupiNVUiLRmQU5pfjB-zpLypr~O1vBFfIew2Q5r-GYKIDsQbYvK7fIGo~JYLBO~AVQ5D60YDpmRpM6zh-MhOm3haE-GhJpMTl4GaUEcTOhcYVwfHGR8NHD79n97Z6t58k1P~J3bMDn~TKTwVVuEcyGCKAsWat31KtqFOc5f-09tIAwrUBjYs1XyqxM3of9vPWfWr~CGjZ6MBOx2c6ULG03KcrpPojQSEV6FaGOl7oOACq8HgCsyeozYo~qiebOrKpmwTw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jamanetworkopen\/939778\/zoi251485t2_1769548137.41544.png?Expires=1777582568&amp;Signature=bCsbqfZqueqDEpHiAj98yeNrTmBZs5AuVJG5SbUTdjK4cmNllh8cZ1kT87Vg9neWWlSgm~NINPyermDYsADEwb8Ig4T7Xz7KJnVTzC4~X1Jsr9~GzQnSrD3h7mCGiM-w-xdpQE5A8Bf6rXiQnAccoAmdCzWjhNWbbOjdhe1uHdJ-CL8WPnHzDXz48mIAG6i~dvoC5lJYJI9j0E~GQUkAPBEUmHbMZnk-40gVkeYPHv~8dH2H44hVZhXAinIJu5pT7Qihfu6wfFKcve1babzd9PjLuXbMUb9b~AaCpFAVzkaWwPAhpldEdtespbpvCgE8KU-iJ3MRjoumluZBNjZBUA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jamanetworkopen\/939778\/zoi251485t3_1769548137.43044.png?Expires=1777582568&amp;Signature=CfQ-lWoPmS0K~-DDRoZalnSTCDfHyuDvZsZBuQlcNPEI5vzjyfnrgcZreuYH7NuSfSFZ1feterSDRR~JNFwZrCtbltKZQnmg6H8mD438Pc~dTDWd1fIyHTcVvWAj2lG2QYK7LwxUic4mYVv9rNeE8sphVdVHwYBQfKa5zujnMkNLbyybZTF-l49cENDvrrJVojeVOW8iZ~f8EYSyE3hA11kDXAa1g4BDkk9IuQT690F5ckDuFcBDNyq7d2cWOH3AMqehTBZOcn6UATt3Js0qW1w-aG2WTzMzYshM253JGedUlhpEeauASOMLjucxVPxRCi1q5U9GKlTADsumFFeUTw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<p><strong>Conclusions and Relevance<\/strong>&nbsp;&nbsp;In this cohort study, most patients following the current protocol had DOAC levels less than 30 ng\/mL, although the proportion of patients with elevated levels was higher for apixaban. Preoperative DOAC levels were not associated with blood loss during surgery.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Original Investigation&nbsp; Surgery Direct Oral Antico [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30169"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30169"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30169\/revisions"}],"predecessor-version":[{"id":30565,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30169\/revisions\/30565"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}